Novo Nordisk Says Higher-Dose Wegovy Shot Helps Some Patients Lose 28% of Their Weight
Wall Street Journal
Last updated: May 12, 2026
Novo Nordisk has announced significant weight loss results for its higher-dose Wegovy injection in a clinical trial. Patients achieved an average body weight reduction of 27.7%, indicating a strong efficacy for the drug in managing obesity.
- Key Findings: A trial involving Novo Nordisk's higher-dose Wegovy injection demonstrated substantial weight loss among participants.
- On average, patients in the trial lost 27.7% of their body weight.
- This finding highlights the potential of Wegovy as a powerful tool for weight management in a clinical setting.
- The drugmaker, Danish pharmaceutical company Novo Nordisk, reported these encouraging results.
- The data suggests a significant advancement in therapeutic options for individuals struggling with obesity.
- Further details of the trial are expected to be released, providing a more comprehensive understanding of the drug's performance and patient outcomes.
